Guangdong Academy of Medical Sciences

Institution (Healthcare)

Homepage ROR

Also Known As

Guangdong Academy of Medical Sciences

15.6K

Publications

991.9K

Citations

1.3K

Authors

1.2K

Concepts

About

Guangdong Academy of Medical Sciences is a healthcare institution in Guangzhou, China known for medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Engineering	60	806	38.3K
2	Health Sciences	55	897	40.8K
3	Arts	4	12	220
4	Education	2	10	254
5	Business	1	1	14

Guangdong Academy of Medical Sciences

15.6K

Publications

991.9K

Citations

Page 1

	Year	Citations
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Caicun Zhou, Yi‐Long Wu, Gongyan Chen, The Lancet Oncology MedicinePathologyBronchial NeoplasmFirst-line TreatmentCancer Treatment	2011	4K
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Tony Mok, Yi‐Long Wu, Iveta Kudaba, The Lancet	2019	3.2K
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer Tony Mok, Yi‐Long Wu, Myung‐Ju Ahn, New England Journal of Medicine	2016	3.2K
CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea R. Doug McEvoy, Nick A. Antic, Emma Heeley, New England Journal of Medicine	2016	2K
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial Yi‐Long Wu, Caicun Zhou, Chengping Hu, The Lancet Oncology Lux-lung 6MedicineRandomised Phase 3PathologyBronchial Neoplasm	2014	2K
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer Yi‐Long Wu, Masahiro Tsuboi, Jie He, New England Journal of Medicine	2020	1.7K
The gut microbiome in atherosclerotic cardiovascular disease Zhuye Jie, Huihua Xia, Shilong Zhong, Nature Communications	2017	1.6K
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials James Chih‐Hsin Yang, Yi‐Long Wu, Martin Schüler, The Lancet Oncology Lux-lung 3Lux-lung 6MedicinePathologyBronchial Neoplasm	2015	1.6K
Spatiotemporal transcriptomic atlas of mouse organogenesis using DNA nanoball-patterned arrays Ao Chen, Sha Liao, Mengnan Cheng, Cell	2022	1.5K
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial Yi‐Long Wu, Ying Cheng, Xiangdong Zhou, The Lancet Oncology OncologyPathologyBronchial NeoplasmDacomitinib Versus GefitinibFirst-line Treatment	2017	1.2K

Page 1